Moderate-to-severe atopic dermatitis is associated with higher lifetime prevalence of multimorbidity and increased odds of ...
A new study from North Carolina State University found that neutrophils—white blood cells that are a key part of the immune ...
Galderma (SIX: GALD), the pure-play dermatology category leader, today released new clinical data confirming nemolizumab’s rapid onset of action on itch and sleep, with significant improvements ...
A German multicentre study reveals strong patient demand for systemic therapy in atopic dermatitis and psoriasis. Learn more about treatment preferences and drivers.
Ruxolitinib cream demonstrated favorable safety and efficacy in pediatric atopic dermatitis, highlighting JAK inhibitors' ...
In this video, Gailen D. Marshall Jr., MD, PhD, chair of allergy and immunology at University of Mississippi Medical Center, discusses the clinical development of the nanobody compound lunsekimig for ...
Dong-A ST announced on December 15 that it has signed an exclusive domestic distribution and sales agreement with Menarini ...
For adults with atopic dermatitis, rocatinlimab treatment yields significant improvements across clinical end points, ...
"Climate change may be exacerbating the rising prevalence and severity of atopic dermatitis." -- Megan Park, BSc, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada Air ...
Rocatinlimab improved moderate to severe dermatitis in adults, establishing the OX40 receptor as a validated treatment target ...
Kymera Therapeutics has announced positive results from its trial of KT-621 to treat patients with moderate to severe atopic ...
Kymera Therapeutics receives US FDA Fast Track Designation for KT-621, an oral STAT6 degrader to treat atopic dermatitis: Watertown, Massachusetts Saturday, December 13, 2025, 18: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback